SDTM conformance errors are often discovered through validation tools, but their root causes usually begin much earlier. They may originate in CRF design, raw data structure, external data transfers, coding conventions, domain mapping decisions, controlled terminology, or metadata management.
For sponsors preparing regulatory submissions, the goal is not only to reduce validation findings. It is to create SDTM datasets that are standard-compliant, clinically coherent, traceable, and reviewable. A dataset package can pass many automated checks and still raise reviewer questions. Likewise, not every validation finding means the data are unusable. The value of expert SDTM review is knowing how to prevent common SDTM conformance errors, identify root causes, correct what should be corrected, and document what requires explanation.

Conformance is not the same as quality

SDTM conformance focuses on whether datasets follow defined standards and validation rules. Data quality is broader. It includes whether the data are accurate, complete, consistent, clinically meaningful, traceable, and fit for regulatory review.
Sponsors need both.
A technically compliant SDTM package may still be difficult to review if domain assumptions are unclear, important data are hidden in supplemental qualifiers, trial design domains are incomplete, or reviewer documentation does not explain key decisions. On the other hand, a validation finding may be acceptable if it reflects a justified study-specific implementation that is clearly documented.
This is why automated validation should be combined with expert standards review.

Missing or incorrect required variables

One common category of SDTM validation errors involves missing required variables or variables populated inconsistently with the standard.
These issues may occur when source data do not contain expected fields, when mapping specifications are incomplete, or when domain requirements are not fully understood.
Examples include missing study identifiers, subject identifiers, domain variables, sequence numbers, timing variables, or required qualifiers. Even when variables are present, errors can occur if values are incorrectly formatted, derived inconsistently, or populated where they should be null.
Prevention starts with strong mapping specifications and early review of source data against expected SDTM domain requirements.

Controlled terminology issues

Controlled terminology errors are among the most frequent SDTM validation findings. They may involve values that do not match CDISC controlled terminology, inconsistent capitalization, outdated terminology versions, sponsor-specific values that were not handled appropriately, or values that should have been mapped to standard terms.
Controlled terminology problems often reflect upstream data collection or coding issues. If sites enter free-text values where controlled options would have been more appropriate, SDTM mapping becomes more difficult.
Sponsors can reduce these issues by aligning CRF design, EDC codelists, coding workflows, and SDTM mapping conventions early in the study.

Timing and date issues

Timing variables are critical for regulatory review and downstream analysis. Errors can occur when study day variables, visit variables, reference dates, start and end dates, or relative timing variables are missing or inconsistent.
Common examples include:

• Inconsistent ISO 8601 date formats.
• Missing reference start dates.
• Incorrect study day derivations.
• Visit names that do not align with trial design.
• Event dates that conflict with exposure or disposition.
• Partial dates handled inconsistently.
• Timing issues are especially important in safety review, treatment-emergent definitions, exposure assessment, and endpoint derivation. They should be reviewed carefully before final SDTM delivery.

Domain structure and variable placement errors

SDTM implementation requires careful decisions about which data belong in which domain and how variables should be represented. Errors can occur when data are forced into the wrong domain, when custom domains are created unnecessarily, or when supplemental qualifiers are used where standard variables would be more appropriate.
Domain structure issues can make data harder to review and may create downstream complications for ADaM programming.
Strong domain mapping requires standards expertise and clinical understanding. The question is not only where the data can technically fit, but where they can be represented most clearly and consistently for review.

Supplemental qualifier misuse

Supplemental qualifiers are sometimes overused as a workaround for data that do not fit neatly into a standard domain. While SUPP domains have a legitimate purpose, overuse can reduce clarity and create traceability challenges.
If important study data are placed in supplemental qualifiers without clear rationale, reviewers may find it harder to understand the dataset. Overuse may also indicate that the SDTM mapping strategy should be reconsidered.
Sponsors should review supplemental qualifier use carefully, especially for data that are clinically important, endpoint-related, or frequently used in analysis.

Define-XML mismatches

A strong SDTM package requires consistency between datasets and Define-XML. Metadata mismatches can create validation findings and reviewer confusion.
Common issues include:

• Variables present in datasets but missing from Define-XML.
• Variables described in Define-XML but not present in datasets.
• Incorrect variable labels.
• Incorrect origins.
• Missing or inconsistent controlled terminology.
• Incomplete value-level metadata.
• Dataset labels that do not match actual content.
• Metadata should be reviewed throughout SDTM development rather than generated only at the end.

Trial design domain issues

Trial design domains are sometimes underprioritized, but they are important for helping reviewers understand planned study structure. Incomplete or inconsistent trial design domains can create review friction, especially in complex studies.
Common issues include mismatches between protocol design and trial design datasets, inconsistent arm or element definitions, and visit structures that do not align with collected data.
These domains should be built with reference to the protocol and reviewed for consistency with actual subject data.

How to Avoid and Fix SDTM Conformance Issues?

The best way to avoid SDTM errors is to treat SDTM as part of the data strategy from the beginning.
Practical steps include:

• Review CRF design with SDTM in mind.
• Define external data transfer specifications early.
• Align coding and controlled terminology expectations.
• Develop detailed SDTM mapping specifications.
• Run validation early and repeatedly.
• Review validation findings for root cause, not only message count.
• Maintain metadata throughout development.
• Involve experienced standards experts in complex mapping decisions.
• Document acceptable findings clearly in the SDRG.
• Perform independent quality review before submission.

The Bioforum Approach: Combining Automation with Standards Expertise

Bioforum supports SDTM mapping, conversion, validation review, Define-XML, SDRG documentation, legacy study conversions, and independent quality review. Our statistical programming teams work with data management and biostatistics to identify issues early and ensure that SDTM datasets support downstream ADaM, TFLs, and submission requirements.
Bioforum’s JetConvert technology helps accelerate SDTM conversion workflows, while expert review ensures that automation is supported by standards knowledge, clinical judgment, and regulatory awareness.

Building SDTM Quality Into the Study Lifecycle

Common SDTM conformance errors are rarely just technical problems. They often reflect gaps in data collection, mapping strategy, controlled terminology, metadata, or documentation.
For sponsors, the priority should be to build SDTM quality into the study lifecycle, validate early, review findings intelligently, and document decisions clearly. The strongest SDTM packages are not only compliant. They are understandable, traceable, and ready for regulatory review.

Partner With Bioforum for Submission-Ready SDTM Data

Need support with SDTM conversion, validation findings, Define-XML, SDRG, or independent SDTM quality review? Bioforum helps sponsors deliver compliant, traceable, and submission-ready clinical data packages.